Lepu Medical(SZ:300003) Zheng Quan Zhi Xing·2025-08-22 16:36Core Viewpoint - The company plans to change the purpose of repurchased shares from "employee stock ownership plan" to "reduce registered capital" and will seek shareholder approval for the cancellation of these shares [5][8]. Summary by Sections 1. Share Repurchase Plan Overview - In 2021, the company approved a share repurchase plan to buy back shares for employee stock ownership, with a maximum price of RMB 35 per share and a total fund of between RMB 30 million and RMB 50 million [1][2]. - By November 1, 2022, the company repurchased 18,273,500 shares, accounting for 0.9653% of the total share capital, with a total expenditure of RMB 355.78 million [2]. 2. Changes in Repurchase Plan - The company decided to terminate the 2022 restricted stock incentive plan due to unmet performance targets and stock price fluctuations [3]. - In 2023, a new repurchase plan was approved with a maximum price of RMB 25 per share and a total fund of between RMB 25 million and RMB 50 million [4]. 3. Change of Purpose for Repurchased Shares - The company intends to change the purpose of 37,215,700 repurchased shares to reduce registered capital, which will require shareholder approval [5][8]. - After the cancellation, the total share capital will decrease from 1,880,611,391 shares to 1,843,395,691 shares [5][7]. 4. Impact of Share Cancellation - The cancellation of repurchased shares is expected to enhance financial metrics such as earnings per share and net asset value without adversely affecting the company's operations or shareholder interests [8]. 5. Approval Process - The board of directors and the supervisory board have both approved the proposal to change the purpose of the repurchased shares and will seek shareholder approval for the necessary amendments to the company's articles of association [9].